Select Your Region
Global
A Study of Atezolizumab in Participants With Programmed Death - Ligand 1 (PD-L1) Positive Locally Advanced or Metastatic Non-Small Cell Lung Cancer
- Cancer
- Lung Cancer
- Non-Small Cell Lung Cancer (NSCLC)
Please note that the recruitment status of the study at your site may differ from the overall study status because some study sites may recruit earlier than others.
Study Status:
Completed
This study runs in
Cities
- Amsterdam
- Ankara
- Antwerpen
- Atlanta
- Aurora
- Badalona
- Baltimore
- Banja Luka
- Barcelona
- Basel
- Boston
- Breda
- Brest
- Bruxelles
- Caen
- Charleroi
- Charlottesville
- Chicago
- Chuo City
- Cincinnati
- Cleveland
- Columbus
- Duarte
- Essen
- Fort Myers
- Fukuoka
- Gilbert
- Groningen
- Großhansdorf
- Habikino
- Heidelberg
- Hershey
- Hirakata
- Hong Kong Island
- Houston
- Huntersville
- İzmir
- Lausanne
- Lebanon
- Leuven
- Limoges
- Ljubljana
- London
- Los Angeles
- Lyon
- Madison
- Malatya
- Marietta
- Melbourne
- Meldola
- Milano
- Minato City
- Montpellier
- Nashville
- Nedlands
- New Haven
- New Hyde Park
- New Territories
- New York
- Nürnberg
- Oldenburg
- Orlando
- Osaka
- Oshawa
- Ottawa
- Philadelphia
- Plovdiv
- Port St. Lucie
- Sagamihara
- Saint-Herblain
- Salt Lake City
- Sanatorio San Luigi
- Sarajevo
- Scottsdale
- Seattle
- Sendai
- Sevilla
- Singapore
- Sofia
- South Pasadena
- St Leonards
- St. Gallen
- St. Louis
- St. Petersburg
- Stanford
- Strasbourg
- Sutton
- T'bilisi
- Toronto
- Vancouver
- Villejuif
- Villingen-Schwenningen
- Washington
- Woolloongabba
- Yokohama
- Zürich
- 横浜市
Trial Identifier:
NCT02031458 2013-003330-32 GO28754
Study Summary
This multicenter, single-arm study will evaluate the efficacy and safety of Atezolizumab in participants with PD-L1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC). Participants will receive Atezolizumab 1200 milligrams (mg) intravenously every 3 weeks as long as participants are experiencing clinical benefit as assessed by the investigator, that is , in the absence of unacceptable toxicity or symptomatic deterioration attributed to disease progression.
Hoffmann-La Roche
Sponsor
Phase 2
Phase
NCT02031458, GO28754, 2013-003330-32
Trial Identifier
Atezolizumab
Treatments
Non-Small Cell Lung Cancer
Condition
Official Title
A Phase II, Multicenter, Single-Arm Study OF Atezolizumab In Patients With PD-L1-Positive Locally Advanced Or Metastatic Non-Small Cell Lung Cancer
Eligibility Criteria
All
Gender
≥18 Years
Age
No
Healthy Volunteers
Inclusion Criteria
- Adult participants greater than or equal to 18 years of age
- Locally advanced or metastatic (Stage IIIB, Stage IV, or recurrent) NSCLC
- Representative formalin-fixed paraffin-embedded (FFPE) tumor specimens
- PD-L1-positive tumor status as determined by an immunohistochemistry (IHC) assay based on PD-L1 expression on tumor infiltrating immune cells and/or tumor cells performed by a central laboratory
- Measurable disease, as defined by RECIST version 1.1
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
Exclusion Criteria
- Any approved anti-cancer therapy, including chemotherapy, or hormonal therapy within 3 weeks prior to initiation of study treatment; the following exception are allowed:
Hormone-replacement therapy or oral contraceptives tyrosine-kinase inhibitors (TKIs) approved for treatment of NSCLC discontinued >7 days prior to Cycle 1, Day 1
- Central nervous system (CNS) disease, including treated brain metastases
- Malignancies other than NSCLC within 5 years prior to randomization, with the exception of those with negligible risk of metastases or death and treated with expected curative outcome
- History of autoimmune disease
- History of idiopathic pulmonary fibrosis (including pneumonia), drug-induced pneumonitis, organizing pneumonia, or evidence of active pneumonitis on screening CT scan. History of radiation pneumonitis in the radiation field (fibrosis) id permitted
- Active hepatitis B or hepatitis C
- Human Immunodeficiency virus (HIV) positive
- Prior treatment with CD137 agonists, anti-CTLA4, anti-PD-1, or anti-PD-L1 therapeutic antibody or pathway-targeting agents
For the latest version of this information please go to www.forpatients.roche.com